Introduction {#s1}
============

Interest in developing new drugs for the treatment of acute heart failure (AHF) remains high and the past, present and future of diuretics, vasodilators and inotropes is source of debate and expectations \[[@R001]\]. Among these three drug therapies, is the inotropic one which is raising the most controversies \[[@R002]\]. While waiting for new promising drugs to be confirmed as serious players \[[@R003]\], the present manuscript aims to review the latest addition to the available repertoire of inotropes and inodilators, levosimendan (*Figure 1).*
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Levosimendan is an inodilator developed for intravenous use in hospitalised patients with acutely decompensated heart failure (ADHF). The pharmacological effects of levosimendan are:

a) increased cardiac contractility mediated by calcium sensitisation of troponin C \[[@R004],[@R005],[@R006],[@R007],[@R008]\];

b) vasodilation through the opening of potassium channels on the sarcolemma of smooth muscle cells in the vasculature \[[@R009],[@R010],[@R011],[@R012]\];

c) cardioprotection through the opening of mitochondrial potassium channels in the cardiomyocytes \[[@R013],[@R014],[@R015],[@R016]\].

Clinical data from heart failure patients show that levosimendan improves haemodynamics \[[@R017],[@R018],[@R019]\] without a significant increase in oxygen consumption \[[@R020],[@R021]\], reduces symptoms of AHF \[[@R017],[@R018],[@R022],[@R023]\], has a beneficial effect on neurohormone levels \[[@R022],[@R023],[@R024]\], has a sustained efficacy due to formation of an active metabolite \[[@R024],[@R025]\], and suffers no loss of effect in patients under beta-blockade \[[@R017],[@R026]\]. Levosimendan offers a predictable safety profile \[[@R017],[@R018],[@R019],[@R023]\], no impairment of diastolic function \[[@R027],[@R028]\], with no development of tolerance \[[@R025]\]. The most common adverse events are hypotension, headache, atrial fibrillation, hypokalemia and tachycardia \[[@R022],[@R023],[@R029]\].

Levosimendan is indicated for the short-term treatment of acutely decompensated severe chronic heart failure in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. In the latest decade, however, levosimendan has been studied in numerous clinical trials outside the field of acute heart failure. Primarily, the drug has been tested in the cardiac surgery settings \[[@R030]\], field in which the drug has shown beneficial haemodynamic and cardioprotective effects and a favorable outcome effect. In addition, several studies with repetitive levosimendan dosing in patients suffering from advanced chronic heart failure have shown beneficial effects on haemodynamics, neurohormone levels and symptoms \[[@R031]\]. Finally, levosimendan has also shown preliminary positive effects - mainly in small-scale studies - in right ventricular failure, cardiogenic shock, septic shock, Takotsubo cardiomyopathy, and in other states requiring inotropic support \[[@R032],[@R033]\].

Our aim is to review the current data, clinical use and future development of levosimendan in all therapy settings envisioning the future development for this drug, the first in class of the cardioprotective inodilators.

 

**CLINICAL DEVELOPMENT**

 

Most of the studies in the regulatory clinical development of levosimendan (*Table 1*) were performed in patients with acute worsening of chronic heart failure. The regulatory clinical development program included about 3,500 patients.
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***Dose-finding study***

The therapeutic dose range of levosimendan administered over a 24-h period was identified in a, double-blind, placebo-controlled study including 151 patients with stable (mainly NYHA class III) heart failure of ischaemic origin. Patients were treated with a bolus dose of levosimendan of 3-36 µg/kg in 10 min followed by a 24-h intravenous infusion at doses ranging from 0.05 to 0.6 μg/kg/min \[[@R019]\].

 

***Dose escalation study***

Up-titration, maintenance and withdrawal of levosimendan were studied in a randomised, double-blind, placebo-controlled study in 146 patients hospitalised for decompensated heart failure (NYHA class III or IV) due to coronary artery disease (60%) or dilated cardiomyopathy (40%) \[[@R018]\]. Patients received an intravenous infusion of levosimendan at doses ranging from 0.1 to 0.4 μg/kg/min. The study was divided into three phases. During the first 6 h, escalated doses of levosimendan (n=98) were compared with placebo (n=48). From 6 to 24 h, patients in the levosimendan group continued to receive the study medication as an open-label infusion. At 24 h, the patients remaining in the study were randomised to continue on levosimendan (levosimendan continuation group) or placebo (levosimendan withdrawal group), administered double-blind up to 48 h \[[@R018],[@R025]\].

 

***LIDO study***

Levosimendan was compared with dobutamine in the LIDO (Levosimendan Infusion versus Dobutamine) study, a double-blind, randomised study in 203 patients with low-output heart failure, who required right heart catheterisation and treatment with an intravenous inotropic drug. Patients randomised to levosimendan were treated with an initial intravenous bolus of 24 μg/kg in 10 min, followed by a 24-h intravenous infusion of levosimendan at doses from 0.1 to 0.2 μg/kg/min \[[@R017]\].

 

***RUSSLAN study***

The safety of levosimendan in patients with left ventricular failure complicating an acute myocardial infarction was studied in RUSSLAN (Randomised Study on Safety and Effectiveness of Levosimendan in Patients with Left Ventricular Failure after an Acute Myocardial Infarct), a placebo-controlled, double-blind, parallel-group, randomised study in 504 patients enrolled within 5 days of an index infarction \[[@R034]\]. Patients randomised to levosimendan were treated with a bolus dose of 6-24 μg/kg in 10 min, followed by a 6-h intravenous infusion at rates ranging from 0.1 to 0.4 μg/kg/min. Invasive haemodynamic data were not collected.

 

***REVIVE studies***

The REVIVE (Randomised Multicenter Evaluation of Intravenous Levosimendan Efficacy) studies (REVIEV I and REVIEV II) evaluated the efficacy of levosimendan on symptoms of heart failure by means of a composite endpoint comprising patients' subjective symptom assessments (at 6 h, 24 h and 5 days) and signs of worsening symptoms (including death) during the 5 days after starting a 24-h trial drug infusion. These two randomised, double-blind, placebo-controlled, parallel-group studies in patients with ADHF were conducted mainly in the U.S.A. REVIVE I (n=100) was a pilot study designed to evaluate the suitability of the chosen composite \[[@R035]\]; REVIVE II (n=600) was a phase III study \[[@R022]\]. Patients randomised to levosimendan (given in addition to current medications) received an initial bolus of 6-12 μg/kg in 10 min, followed by a 24-h intravenous infusion at rates of 0.1 to 0.2 μg/kg/min.

 

***SURVIVE study***

The SURVIVE (Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support) study was a double-blind, randomised study in 1327 patients with severe systolic heart failure comparing the effects of levosimendan with dobutamine on mortality. Patients in the levosimendan arm were treated (on top of current AHF medications) with a bolus of 12 μg/kg in 10 min, followed by a 24-h intravenous infusion of 0.1 to 0.2 μg/kg/min \[[@R023]\].

 

**MAIN THERAPEUTIC EFFICACY AND SAFETY DATA**

 

***Haemodynamics***

Levosimendan has repeatedly been shown to produce significant dose-dependent increases in cardiac output, stroke volume and heart rate, and decreases in pulmonary capillary wedge pressure, mean blood pressure, mean pulmonary artery pressure, mean right atrial pressure and total peripheral resistance \[[@R019]\].

The effect of levosimendan on haemodynamic variables (cardiac output, stroke volume, heart rate and pulmonary capillary wedge pressure) are clearly evident already at the end of a 5-min bolus infusion \[[@R036]\]. There is no sign of development of tolerance even with a prolonged infusion up to 48 h \[[@R025]\]. Haemodynamic effects are maintained up to 7-9 days after stopping levosimendan infusion, due to the formation of an active metabolite, designated OR-1896 \[[@R024]\].

Compared with dobutamine, levosimendan produces a slightly greater increase in cardiac output and a profoundly greater decrease in pulmonary capillary wedge pressure \[[@R017],[@R037]\]. In contrast to dobutamine, the haemodynamic effects are not attenuated with concomitant beta-blocker use \[[@R017]\]. At 48 h after the start of infusion in beta-blocked patients with severe ADHF, a 24-h infusion of levosimendan achieves better haemodynamic effects than a 48-h dobutamine infusion \[[@R037]\].

 

***Blood pressure***

The data from REVIVE show that levosimendan significantly decreases blood pressure compared to placebo \[[@R022]\]. Accordingly, the current Summary of Product Characteristics (SPC) labelling suggests levosimendan be used with caution in patients with low baseline systolic or diastolic blood pressure or those at risk for a hypotensive episode.

Post-hoc analyses of the REVIVE studies identified systolic blood pressure \< 100 mmHg or diastolic blood pressure \< 60 mmHg at baseline as a factor increasing mortality risk \[[@R022],[@R038]\]. Conversely, in patients with higher blood pressure at baseline (systolic ≥ 100 mmHg and diastolic ≥ 60 mmHg), mortality was 8% with levosimendan and 9% with placebo (p = 0.81). Of importance is the finding that the primary composite endpoint was still positive and statistically significant in this subgroup \[[@R038]\].

 

***Symptoms***

Dyspnoea improved in significantly more patients treated with levosimendan compared with placebo at 6 hours after the start of treatmentin one early controlled trial in severe heart failure \[[@R018]\]. On the other hand, in the LIDO study \[[@R017]\], symptoms of dyspnoea and fatigue improved equally well in levosimendan-or dobutamine-treated patients at 24 h after the start of infusion.

In the REVIVE II study, symptoms over the 5-day assessment period improved significantly more with levosimendan than with placebo \[[@R022]\]. It should be noted that in REVIVE levosimendan (or placebo) was administered on top of the standard of care and that in the placebo group, the majority of the patients also improved vs baseline.

 

***Composite end point***

In the REVIVE II study, the primary endpoint was a composite consisting of patients' subjective symptom assessments (at 6 hours, 24 hours, and 5 days) and signs of worsening symptoms (including death) during the 5 days after starting a 24-h trial drug infusion. Improvement was observed more frequently (19% vs 15%) and worsening less frequently (19% vs 27%) in levosimendan treated patients compared with placebo (p = 0.015) \[[@R022]\]. The improvement in the composite endpoint was accompanied by a lower need for rescue medication in the levosimendan group \[[@R022],[@R038]\].

 

***Neurohormones***

Several studies indicate that levosimendan produces a rapid and sustained decrease in natriuretic peptides. Lilleberg et al. \[[@R024]\] found that a 24-h levosimendan infusion induced a 40% decrease in plasma N-terminal atrial natriuretic peptide and N-terminal pro-BNP (NT-proBNP) levels and the treatment effect was estimated to last up to 16 and 12 days, respectively. In the SURVIVE study, a similar decrease in BNP was seen \[[@R023]\] but duration of the effect could not be determined as the last time-point for measuring BNP was 5 days. In the REVIVE II study the significant effect on BNP was also evident until day 5 \[[@R022]\].

 

***Mortality***

In the LIDO study, mortality was followed as a secondary endpoint for 31 days. During that time, 8% of patients assigned to levosimendan died, compared with 17% assigned to dobutamine (p = 0.049). The follow-up was retrospectively extended to 180 days, at which point the respective figures were 26% for levosimendan and 38% for dobutamine (p = 0.029) \[[@R017]\]. Mortality in the RUSSLAN study \[[@R034]\] was prospectively followed for 14 days after starting treatment and shown to be significantly lower with levosimendan than with placebo (12% vs 20%; p = 0.031). There was a trend for this positive effect to persist up to 180 days in a retrospective analysis (23% vs 31%; p = 0.053). In the REVIVE II study \[[@R022]\], mortality was numerically, but not statistically significantly, higher in the levosimendan group, with 45 (15%) deaths in the levosimendan group and 35 (12%) in the placebo group during the 90-day study period (p = 0.21). In the SURVIVE study \[[@R023]\] there was no significant difference in survival between levosimendan and dobutamine (26% vs 28%, hazard ratio 0.91; 95% CI, 0.74-1.13; p = 0.40). A majority (88%) of patients in this study had a history of ADHF. In these patients, mortality at 31 days was significantly lower with levosimendan than with dobutamine (p = 0.046) \[[@R026]\]. Similarly, mortality was significantly lower with levosimendan than with dobutamine in the subset of patients receiving concomitant beta-blockers \[[@R026]\].

Several meta-analyses on the effect of levosimendan on mortality have been recently published \[[@R039],[@R040],[@R041],[@R042],[@R043],[@R044]\]. Among these, the investigation by Landoni et al. \[[@R040]\] is the most comprehensive and statistically the most robust. It included 45 clinical trials with intravenous levosimendan with a total of 5480 patients. Levosimendan significantly reduced mortality both in cardiology and cardiac surgery settings, and both against dobutamine and placebo.

A registry study, ALARM-HF (Acute Heart Failure Global Survey of Standard Treatment), reviewed in-hospital treatments in eight countries \[[@R045]\].Unadjusted analysis showed a significantly higher in-hospital mortality rate in patients receiving intravenous inotropes (25.9%) compared to those who did not (5.2%) ( p \< 0.0001 ). A propensity-based analysis was performed to compare in-hospital mortality in patients treated only with intravenous levosimendan versus those treated only with catecholamines within 24 h of therapy initiation. Propensity score matching produced 104 matched pairs and showed that the use of levosimendan resulted in a significant reduction in the risk of in-hospital mortality (hazard ratio 0.25, 95% CI 0.07-0.85).

 

***Hospitalization***

A way to evaluate the effect of a medication on both mortality and morbidity is to assess the number of days a patient is both alive and out of hospital during the follow-up period. In the LIDO study, patients in the levosimendan group spent significantly more days alive and out of hospital than dobutamine-treated patients in a retrospective 180-day follow-up analysis (median 157 vs. 133 days for levosimendan and dobutamine, respectively; p = 0.027) \[[@R017]\].

In the REVIVE II study, the mean duration of the initial hospitalisation was almost 2 days shorter in the levosimendan group (7.0 days) than in the placebo group (8.9 days) \[[@R022],[@R038]\]. Significantly more patients treated with levosimendan were released within 5 days and fewer had extended hospitalisations (p = 0.008).

In a recent single center study \[[@R046]\] that compared levosimendan with standard of care in a population of AHF patients, the mean length of hospitalization was 12.1 and 13.6 days in the levosimendan (n=147) and control groups (n=147), respectively (p \< 0.05). Re-hospitalization rates were lower in the levosimendan group at 12 months (7.6 vs 14.3%; p \< 0.05), and mortality rates at 1 month were 2.1% vs 6.9%, respectively (p \< 0.05). In conformity with these observations from individual studies, in the earlier-mentioned meta-analysis by Landoni et al. \[[@R040]\] the mean length of stay in hospital was 1.59 (95% CI 0.85-2.33) days shorter in levosimendan-treated patients in the cardiology setting (p \< 0.0001).

 

***Renal function***

Renal function often worsens in patients with AHF, and this deterioration is associated with adverse outcome. Studies show improved serum creatinine levels in levosimendan-treated patients \[[@R047],[@R048]\].

Estimated glomerular filtration rate (eGFR) improved in levosimendan compared to dobutamine treated patients with heart failure who required inotropic therapy \[[@R049]\]. A placebo-controlled study in patients hospitalized for decompensated heart failure and renal dysfunction, showed a statistically significant improvement in eGFR in levosimendan treated patients. Peak effect was seen at 3 days after a 24-h infusion, with discernible effects persisting up to 14 days \[[@R050]\]. In addition to beneficial effects on central hemodynamics, levosimendan has direct effects on renal circulation and induces preglomerular vasodilation \[[@R051]\], leading to improved renal blood flow and glomerular filtration rate \[[@R052]\]. The renal oxygen demand/supply relationship is not affected by levosimendan \[[@R051]\]. In a meta-analysis of 4 randomized studies on the effect of levosimendan in cardiac surgery, a reduction in the rate of acute renal failure was seen in favor of levosimendan treated patients (odds ratio 0.26 \[96% CI 0.12-0.60\], p = 0.002, with 228 patients included) \[[@R053]\]. Interestingly, a study was just started on the effect of Levosimendan in Acute Kidney Injury (LAKIS, NCT01720030).

Severe renal failure is a contraindication for levosimendan use as no formal pharmacokinetic studies in heart failure patients with severe renal failure have been conducted. However, many heart failure patients in large regulatory studies such as REVIVE and SURVIVE had severe renal failure \[[@R022],[@R023],[@R026]\]. According to pharmacokinetic study in severe renal impairment, the elimination of the levosimendan metabolites was prolonged. The results suggest that if levosimendan was given to heart failure patients with severe renal impairment, the dose should be reduced \[[@R054]\].

 

***Effects on other organs***

Some reports on a positive effect of levosimendan on splanchnic \[[@R055]\], liver \[[@R056],[@R057]\], and diaphragm functions \[[@R058]\] have been published. It must be highlighted, however, that these data were not collected in an AHF population, but in other settings, such as septic shock, cardiac surgery, or chronic obstructive pulmonary disease (COPD).

 

***Adverse events***

Levosimendan infusion has generally been well tolerated in the AHF population, despite the high-risk nature of these patients. Hypotension was seen more frequently with levosimendan than with placebo \[[@R022]\], but not when levosimendan was compared with dobutamine \[[@R023]\].

Levosimendan has been associated with a higher incidence of atrial fibrillation compared both with placebo \[[@R022]\] and with dobutamine \[[@R023]\]. However, conflicting results have been presented with regard to ventricular arrhythmias. In REVIVE a higher incidence of ventricular tachycardia was observed with levosimendan compared with placebo \[[@R022]\]. In SURVIVE, ventricular tachycardia was observed with similar frequency in the levosimendan and dobutamine groups \[[@R023]\]. In both studies, cardiac failure as an adverse event was less frequent in levosimendan arm, although the result was statistically significant only in SURVIVE.

 

***Safety laboratory values***

The changes in safety laboratory variables have been modest in levosimendan studies. A decrease in potassium levels has been seen with levosimendan more often than with comparators \[[@R019]\]. Clinically insignificant decreases in haemoglobin and erythrocyte counts have been observed \[[@R019]\].

 

**CLINICAL TRIALS SETTINGS OTHER THAN ADHF**

During the past years, various independent research groups have described the use of levosimendan in a range of clinical situations other than ADHF, *e.g.* advanced chronic heart failure, cardiogenic- and septic-shock, cardiac- and non-cardiac surgery, etc. Hereby we review the most recent literature.

 

***Advanced chronic heart failure***

Patients with refractory heart failure are hospitalised frequently for clinical deterioration. During such admissions, they often receive infusions of positive inotropes (dobutamine, dopamine, or milrinone) and vasodilators in an effort to improve cardiac performance, facilitate diuresis and promote clinical stability \[[@R059]\].

Despite favourable haemodynamic and symptomatic improvement in small clinical studies, concerns have been raised about the safety of intermittent or continuous inotropic therapy. Both dobutamine and milrinone increase the myocardial oxygen demand and intracellular calcium concentration, thus increasing the risk of arrhythmic events and, possibly, death \[[@R060],[@R061]\].

A number of small-scale investigator-initiated studies, in which levosimendan has been administered repeatedly to patients with advanced chronic heart failure, have been reported and are summarized below. In general, the results suggest that levosimendan improves haemodynamics, neurohormones and clinical outcomes. However, the optimal dosing scheme has not been established.

Nanas et al. \[[@R062]\] exposed 36 consecutive patients with NYHA class IV heart failure, resistant to a 24 h continuous infusion of dobutamine: a group was exposed to continuous infusion of dobutamine 10 mg/kg/min for at least 48 h, followed by weekly (or more often if needed) intermittent dobutamine infusions of 8 h (n=18) while the second group, after the initial 24 h infusion of dobutamine, to a 24 h infusion of levosimendan (0.2 mg/kg/min) followed by further biweekly 24 h infusions at the same dose. The addition of intermittent levosimendan infusions was associated with a prolonged survival (45-day survival of 6% vs 61%; p=0.0002).

Mavrogeni et al. \[[@R063]\] performed an open-label prospective study in 50 patients with advanced heart failure (NYHA III or IV). Half of the patients received 24 h infusions of levosimendan (0.1-0.2 mg/kg/min after a 6 mg/kg loading dose) given monthly for 6 months in addition to standard of care and half of the patients were treated with standard of care. At the end of the study, the proportion of patients reporting improvement in symptoms of heart failure was larger in the levosimendan group than in the control group (65% vs 20%; p \<0.01). After 6 months, the levosimendan group had a significant increase in left ventricular ejection fraction (LVEF) (28±7% vs controls 21±4%; p=0.003). Twenty-four hours Holter-recordings revealed no significant changes in the occurrence of atrial or ventricular arrhythmias between the two groups. Two patients in the levosimendan group died during the 6-month follow-up period, compared with 8 patients in the control group (p \<0.05) \[[@R063]\].

Parle et al. \[[@R064]\] reported on 44 consecutive heart failure patients with systolic impairment, who received between 2 and 26 repeated infusions of levosimendan. The bolus dose was omitted in 65% of administrations and the maximum maintenance infusion was 0.2 mg/kg/min in 60% of patients. The interpretation of efficacy and safety is hampered by the absence of a control group. However, a significant drop in BNP levels and NYHA class was observed and overall the infusions were judged to be well-tolerated.

Parissis et al. \[[@R065]\] performed an open-label, randomised, placebo-controlled study in 25 patients with decompensated chronic heart failure. Five 24 h infusions of levosimendan (a bolus of 6 mg/kg/10 min followed by an infusion of 0.1 mg/kg/min) were given to 17 patients in a 3 weeks interval. Levosimendan treatment was accompanied by significant reductions in cardiac end-systolic and end-diastolic dimensions and volume indices ( p \< 0.01 vs baseline ). The effects of long-term, intermittent treatment of levosimendan, dobutamine, and the combination of levosimendan with dobutamine on outcomes have recently been studied in 63 patients with decompensated end-stage heart failure. Three groups, each of 21 patients, were assigned to dobutamine 10 mg/kg/min, to levosimendan 0.3 mg/kg/min, or to dobutamine 10 mg/kg/min and concomitant levosimendan 0.2 mg/kg/min. The durations of the infusions were 6 h, and the drugs were given weekly for 6 months. In addition, all patients received oral amiodarone (400 mg/day). The 6-month survival was 80% in the levosimendan-only group, 48% in the dobutamine-only group and 43% in the combined group. Cardiac index was significantly increased and pulmonary capillary wedge pressure significantly decreased only in the levosimendan group \[[@R066]\].

Moreover, a study was conducted in 28 patients with pulmonary hypertension of various etiologies (including secondary to left-sided heart failure) \[[@R067]\]. Patients were randomised 2:1 to levosimendan and placebo and they received in total five infusions. The initial 24 h levosimendan infusion (12 mg/kg bolus followed by the maintenance infusion of 0.1-0.2 mg/kg/min) produced a significant decrease in pulmonary vascular resistance. Thereafter, levosimendan was administered every 2 weeks as a 6-h infusion with the infusion rate of 0.2 mg/kg/min. These repeated administrations were found to be safe and the effect on pulmonary vascular resistance was maintained throughout the course of treatment.

Finally, the largest study with repetitive dosing with levosimendan is the LevoRep (Randomised trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure) study \[[@R031]\], a randomised, double-blind, placebo-controlled study in advanced chronic heart failure. Levosimendan was administered as 6-h infusions (0.2 mg/kg/min) every 2 weeks for 8 weeks (four infusions per patient). Publication of the final results of LevoRep is awaited. Meanwhile, three similar studies has been started: the Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients study (LION-HEART, NCT01536132), the Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Study Efficacy, Security, and Long Term Effects of Intermittent Repeated Levosimendan Administration in Patients with Advanced Heart Failure (LAICA, NCT00988806), and the Early LEvosimendanVs Usual Care in Advanced Chronic hearTfailurE (ELEVATE, NCT01290146).

 

***Right ventricular failure***

Right ventricular failure is most commonly related to left ventricular heart failure. Biventricular failure has a worse outcome than pure left ventricular failure. In isolated right ventricular failure there is low output syndrome in the absence of pulmonary congestion, with increased jugular venous pressure, with or without hepatic congestion, and a low left ventricular filling pressure. Right ventricular failure can be caused by myocardial ischemia, volume overload and/or pressure overload \[[@R068]\]. Investigator initiated studies have been performed in patients with right ventricular failure. In these studies, levosimendan has been shown to:

1\) reduce the increased right ventricular afterload;

2\) improve right ventricular contractility;

3\) improve diastolic function of the right ventricle.

Parissis et al. \[[@R069]\] reported that, in a placebo-controlled study in 54 patients with advanced right ventricular heart failure (NYHA III-IV, LVEF \<35%), levosimendan (0.1-0.2 μg/kg/min for 24 h) improved Doppler echocardiographic markers of systolic and diastolic right ventricular function. Poelzl et al. \[[@R070]\] administered open-label levosimendan (bolus in the range of 6-12 μg/kg and infusion in the range of 0.075-0.2 μg/kg/min for 24 h) to 18 patients with AHF (characterized by LVEF ≤30%, cardiac index ≤2.5 l/min/m^2^, right atrial pressure ≥10 mmHg, pulmonary capillary wedge pressure ≥15 mmHg) and observed improved right ventricular contractility but not any change in right ventricular afterload.

Russ et al. \[[@R071]\] evaluated right ventricular function in 25 consecutive acute myocardial infarction patients with cardiogenic shock not responding sufficiently to conventional treatment. A 24 h levosimendan infusion (12 μg/kg bolus in 10 min, followed by a dose of 0.1-0.2 μg/kg/ min) decreased pulmonary vascular resistance and improved cardiac power index (both right and left ventricles), indicating decreased right ventricular afterload and improved right ventricular contractility.

Morelli et al. \[[@R072]\] studied 35 mechanically ventilated patients with acute respiratory distress syndrome (ARDS) related to septic shock. Patients were treated with a 24 h infusion of levosimendan (0.2 μg/kg/min, n=18) or placebo (n=17). Reductions in pulmonary vascular resistance and mean pulmonary arterial pressure, and improvements in cardiac index, right ventricular ejection fraction and mixed venous oxygen saturation were observed only in the levosimendan group.

 

***Cardiogenic shock***

Cardiogenic shock is a rare but often fatal complication of acute coronary syndrome. The underlying pathophysiology is profound depression of myocardial contractility and the state can be defined as decreased cardiac output and evidence of tissue hypoxia in the presence of adequate intravascular volume \[[@R073]\]. The standard of care consists of primary percutaneous coronary intervention for ST-elevated myocardial infarction, fluid therapy, vasopressors and inotropes \[[@R074]\]. The role of intra-aortic balloon pump (IABP) counter-pulsation has recently been challenged \[[@R075]\]. Data describing the use of levosimendan in cardiogenic shock are still scarce. Nevertheless, the drug appears to be safe and to improve some haemodynamic and ventricular indices \[[@R069],[@R076],[@R077],[@R078]\]. The improved survival reported by Fuhrmann et al. \[[@R079]\] is notable (30 day survival 69% with levosimendan vs 37% with enoximone; p=0.023, n=32), but the current dataset is too small to draw definitive conclusions.

 

***Septic shock***

Sepsis and septic shock are among the leading causes of death in intensive care units (ICUs) with associated mortality rates up to \~50% \[[@R080]\]. Sepsis frequently causes myocardial depression of both ventricles via an impaired response of beta-receptors to endogenous and exogenous catecholamines and via diminished sensitivity of contractile myofilaments to calcium. The results of the few investigator-initiated studies with levosimendan in septic shock support the possibility that levosimendan may have some beneficial effects in this highly vulnerable patient population.

Morelli et al. \[[@R081]\] randomly exposed 28 septic patients with persisting left ventricular dysfunction after 48 h of conventional treatment to receive a 24 h infusion of either levosimendan (0.2 mg/kg/min, n=15) or dobutamine (5 mg/kg/min, n=13). In addition to improved haemodynamics, levosimendan increased gastric mucosal flow, creatinine clearance and urinary output and decreased lactate levels, without negatively affecting mean arterial pressure. Reports by the same author \[[@R072]\] of favourable effects of levosimendan in patients with sepsis-related ARDS have already been noted in this review (see section on "Right ventricular failure"). A 500-patient study sponsored by the NIHR-EME program is shortly to commence in the UK (led by Dr. A.C. Gordon in conjunction with the Imperial Clinical Trials Unit) assessing the role of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS, ISRCTN12776039). This double-blind randomised placebo-controlled trial will test if levosimendan, when added to standard of care, reduces multiple organ failure and improve patient outcome.

 

***Weaning from ventilator***

Acquired diaphragm muscle weakness is a key feature in several chronic conditions, including COPD and congestive heart failure, and patients who are difficult to wean from mechanical ventilation \[[@R082]\]. About 10-20% of intubated patients in ICUs are difficult to wean from mechanical ventilation, resulting in increased morbidity, mortality and health care costs \[[@R083]\].

The pathophysiology of muscle weakness in these patients is complex, but includes muscle fiber atrophy and reduced calcium sensitivity of the contractile proteins \[[@R084]\]. As respiratory muscle troponin resembles cardiac troponin, it is plausible that levosimendan may enhance contractility in the same way it enhances cardiac contractility.This supposition has support from *in vitro* data \[[@R058]\], experimental observations \[[@R085]\], and a healthy volunteer study \[[@R082]\]. Positive effects were seen both in slow and rapid diaphragm muscle fibers \[[@R058],[@R085]\].

Mechanical ventilation results in rapid loss of diaphragmatic force production \[[@R086]\]. In addition, shifting from mechanical ventilation to spontaneous ventilation may dramatically increase left ventricular filling pressure and pulmonary artery pressure, especially in patients with pre-existing cardiac and or pulmonary comorbidities.

Levosimendan was compared to dobutamine in difficult-to-wean COPD patients \[[@R087]\]. Levosimendan resulted in significantly greater inhibition of spontaneous ventilation induced increase in pulmonary artery occlusion pressure. Similarly, mean pulmonary artery pressure increased to a lesser extent with levosimendan than with dobutamine. In a prospective observational study in ventilator-dependent difficult-to-wean ICU-patients with diminished left ventricular function (LVEF \<40%), levosimendan improved cardiac contractility and oxygenation variables and increased the likelihood of separation from mechanical ventilation \[[@R083]\]. A study on the Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients (NCT01721434) run at the University Medical Center Nijmegen is currently recruiting.

 

***Cardiac surgery***

Peri-operative acute cardiovascular dysfunction occurs in more than 20% of patients undergoing cardiac surgery; yet current AHF classification \[[@R068]\] is not applicable to this period. Indicators of major perioperative risk include unstable coronary syndromes, decompensated heart failure, significant arrhythmias and valvular disease. Clinical risk factors include history of heart disease, including heart failure, cerebrovascular disease, presence of diabetes mellitus, renal insufficiency and high-risk surgery \[[@R088]\].

Preserving heart function during cardiac surgery is a major goal. However, optimal perioperative use of inotropes and vasopressors in cardiac surgery remains controversial. Neither is the use of an IABP or left ventricular assist device (LVAD) risk-free \[[@R089],[@R090]\]. The comparative data on levosimendan in this situation suggest that it has the potential to become a drug of choice among the agents with inotropic properties, possibly due to its cardioprotective qualities.

Several studies have demonstrated that levosimendan protects the myocardium and improves tissue perfusion, while minimising tissue damage during the cardiac surgery and reperfusion periods \[[@R020],[@R033],[@R091]\]. Current data from individual studies and meta-analyses suggest that levosimendan is superior to traditional inotropes (dobutamine, phosphodiesterase-inhibitors), delivering sustained haemodynamic improvement, diminished myocardial injury, and better outcomes \[[@R092],[@R093]\].

Tritapepe et al. \[[@R094]\] performed a randomised, double-blind, placebo-controlled study in 106 patients undergoing elective multivesselcoronary artery bypass grafting (CABG). Levosimendan (bolus only, 24 μg/kg over 10 min), or placebo was given before initiation of cardiopulmonary bypass (CPB). Mean tracheal intubation time and length of ICU stay were significantly shorter in the levosimendan group (both p\<0.01) and the number of patients needing inotropic support for \>12 h was significantly lower with levosimendan (18.0% vs 3.8%; p = 0.021). Significantly higher postoperative values of mean arterial pressure, cardiac index and cardiac power index, and a lower systemic vascular resistance index were observed with levosimendan, while troponin I increases were significantly smaller ( all p \< 0.005 or less ).

In a placebo-controlled study in 60 patients undergoing CABG Eriksson et al. showed that levosimendan (0.2 µg/kg/min, 24 h) increases the success of primary weaning from CPB (73% vs 33%, p=0.002) \[[@R033]\].

Lahtinen et al. \[[@R095]\] reported a randomised, double-blind, placebo-controlled study in 200 patients assigned to undergo heart valve or combined heart valve and CABG surgery. Levosimendan was given as a 24-h infusion started at the induction of anaesthesia with a 24 µg/kg bolus over 30 min and thereafter at a dose of 0.2 µg/kg/min. The primary outcome measure was heart failure, defined as cardiac index 2 or failure to wean from CPB necessitating inotrope administration for at least 2 hours postoperatively after CPB. Heart failure was less frequent in the levosimendan group than in the placebo group (15% vs 58%; p\<0.001). Need of inotrope use for rescue was also lower in the levosimendan group (risk ratio 0.11; 95% CI 0.01-0.89), and IABP was utilised in one patient (1%) in the levosimendan versus nine (9%) in the placebo group (risk ratio 0.11; 95% CI 0.01-0.87). Creatine kinase was lower in the levosimendan group on the first post-operative day (p=0.011). The levosimendan group had more hypotension and needed norepinephrine more often (83 vs 52, p\<0.001). There was no difference in in-hospital or 6-month mortality (overall, 12% of the patients died in both groups).

The meta-analysis by Landoni et al. \[[@R040]\] on mortality with intravenous levosimendan identified 17 studies in cardiac surgery, including 1233 patients. Levosimendan reduced mortality significantly in cardiac surgery patients compared with the control arms (5.8% vs 12.9%; risk ratio 0.52, 95% CI 0.35-0.76). 

In another independent meta-analysis, Maharaj and Metaxa \[[@R041]\] reported a favourable effects of levosimendan on cardiac index (mean difference 1.63, 95% CI 1.43-1.83, p\<0.00001), length of ICU stay (mean difference -26 hours 95% CI -46 to -6, p=0.01), rate of atrial fibrillation (odds ratio 0.54, 95% CI 0.36-0.82, p=0.004), and troponin I levels (mean difference -1.59, 95% CI 1.78-1.40, p\<0.00001) as well as a mortality reduction after coronary revascularisation (odds ratio 0.40, 95% CI 0.21-0.76, p=0.005). These data amplified the findings of previous meta-analyses \[[@R042],[@R044],[@R053]\].

Recently, a group of experts published a consensus report on how to use levosimendan in cardiac surgery \[[@R030]\] and the study Levosimendan in High Risk Patients Undergoing Cardiac Surgery (HSR-LEVO, NCT00994825) was initiated and is currently recruiting. Of interest also two recent papers on reduction of perioperative mortality \[[@R096],[@R097]\] in which levosimendan is cited as a drug with potential to reduce mortality in surgical settings.

 

***Non cardiac surgery***

Congestive heart failure is a non-uncommon co-morbidity in patients undergoing non-cardiac surgery, and is strongly associated with a doubling of the in-hospital mortality \[[@R098]\]. Some authors have suggested a role for levosimendan in the preoperative optimization of cardiac function in patient undergoing major elective non-cardiac surgery \[[@R099]\]. Katsaragakis et al. reported on the use of levosimendan in high risk patients undergoing abdominal surgery \[[@R100]\], while Ponschab et al. \[[@R101]\] described how levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair. Both groups demonstrated that the administration of levosimendan was safe and observed improvements in ejection fraction, echochardiographic parameters as well as a range of haemodynamic indices both intra- and postoperatively. Therefore, Morelli et al. suggested that the prophylactic administration of levosimendan in patients with compromised myocardial physiologic reserve, undergoing anesthesia and major non-cardiac surgery, is safe and advisable for preoperative cardiac optimization \[[@R099]\].

 

***Paediatric use***

In the paediatric cardiac settings, inotropic support is often employed on the basis of extrapolations from adult studies, the underlying pathophysiology, the pharmacodynamics of inotropes, and anecdotal experience. There are currently no official indications for levosimendan in patients under 18 years of age (see levosimendan SPC), but the drug has been indeed studied and used as a rescue drug in the paediatric ICU (PICU) and in the operating room. The published paediatric experience in levosimendan comprises mainly observational studies \[see recent reviews by Hoffman \[[@R102]\] and by Angadi et al. \[[@R103]\]\] or analyses of patient registers \[[@R104]\], but also four randomised and blinded trials have been reported \[[@R105],[@R106],[@R107],[@R108]\]. All in all, 645 patients were included in 14 reports.

The pharmacokinetic profile of levosimendan in children with congenital heart disease is similar to that in adult patients with congestive heart failure \[[@R109]\]. Ten hours after the initiation of 48 hours levosimendan infusion in neonates undergoing cardiac surgery, the active metabolite OR-1896 was detectable in plasma and remained measurable up to 14 days \[[@R106]\]. This observation suggests that levosimendan will exert prolonged hemodynamic effects in neonates after cessation of infusion similar to those noted in adults.

As it regards the doses, levosimendan has been administered in children without or with a bolus dose of 6-24 mcg/kg, and by infusion of 0.05 to 0.2 mcg/kg/min similarly to adults. Levosimendan infusions have been well tolerated in children with acute heart failure or children who are undergoing cardiac surgery; only transient hypotension or tachycardia has been reported in the beginning of the infusion. The largest published data in paediatrics included retrospectively-gathered data on 484 levosimendan infusions delivered to 293 patients at a single PICU \[[@R104]\]. A majority of the patients (65%) were aged 12 months or younger. Most of the physicians surveyed (89%) thought that levosimendan postponed or reduced the need for mechanical cardiac support in children with cardiomyopathy or who were undergoing cardiac surgery. Levosimendan was shown to be as efficacious as milrinone with comparable hemodynamic data in two randomised and double-blind studies in children and in neonates undergoing cardiac surgery \[[@R107],[@R110]\]. In another comparison of milrinone and levosimendan in neonates undergoing cardiac surgery, levosimendan group had higher pH, lower blood glucose level and lower inotrope score in the PICU \[[@R106]\].

In a randomised double-blind study in children younger than 4 years of age undergoing cardiac surgery, patients receiving levosimendan had significantly higher cardiac index and lower pulmonary artery pressure than children receiving dobutamine \[[@R108]\]. Of interest is a report describing a strategy for rotating inotropes in pediatric decompensated heart failure \[[@R111]\].

 

***Other clinical settings***

Case reports, uncontrolled small series or small-scale comparative studies with levosimendan have been published *e.g.*in calcium-channels-blockers intoxication \[[@R112]\] and Takotsubo cardiomyopathy \[[@R113],[@R114]\].

Conclusion {#s4}
==========

**GUIDANCE FOR CLINICAL USE, FUTURE DEVELOPMENTS**

 

Its pharmacologic and pharmacodynamic properties differentiate levosimendan from other inotropes.

The infusion of levosimendan has consistently been shown to enhance left ventricular performance and to decrease left ventricular filling pressure and plasma BNP concentrations without increasing myocardial oxygen consumption (*Table 2*).

![Clinical effects of levosimendan.](hlv-05-227-g003){#F003}

Neither age nor gender influence the responses to levosimendan. Following a 24-h infusion of levosimendan, the active metabolite reaches pharmacologically active plasma levels, resulting in a prolonged haemodynamic effect \[[@R115],[@R116]\], wich persists for at least 7 days \[[@R024]\]. for at least 7 days \[[@R024]\].

The haemodynamic and neurohumoral improvement is associated with a symptomatic benefit that is sustained and superior to that of placebo. In contrast to dobutamine, the effects of levosimendan are not attenuated with concomitant beta-blocker use \[[@R026]\].

In two early phase III studies, a significant mortality benefit with levosimendan was observed in comparison with both placebo (RUSSLAN) and dobutamine (LIDO). These favourable results were not, however, confirmed in two subsequent studies where levosimendan was compared with placebo (REVIVE) and dobutamine (SURVIVE). Subgroup analyses from the SURVIVE study indicate that levosimendan outperforms dobutamine in beta-blocked patients and in patients with acute decompensation of an existing chronic failure. Recent independent meta-analyses on the effect of levosimendan on mortality suggest a survival benefit of levosimendan both compared to placebo and dobutamine; a trend towards a more favourable outcome effect was noted with lower levosimendan doses (≤0.1 µg/kg/min) \[[@R040]\].

Dosing guidance for levosimendan in ADHF (*Table 3*) may be proposed from the experience of controlled trials. Levosimendan infusion has generally been well tolerated.
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Levosimendan infusion has generally been well tolerated.

Data from the REVIVE and SURVIVE studies - the two largest studies conducted to date- indicate that hypotension was more frequent with levosimendan than with placebo, though not dobutamine. Levosimendan was also associated with higher incidence of atrial fibrillation relative to both those comparators.

It should be recalled that, in addition to contractility increasing effects, levosimendan has profound vasodilatory effects. Clinical studies have indicated that levosimendan should be given cautiously to patients with low blood pressure, especially in case of hypovolaemia.

Use of lower infusion rates without the loading bolus should be considered for such patients. In case of unintended overdose, pronounced haemodynamic effects would be expected; mainly hypotension and increased heart rate/arrhythmias. Hypotension should be treated with fluid resuscitation and vasoconstrictors, as needed. Arrhythmias may be treated with intravenous beta-blockade or amiodarone (if blood pressure allows). Due to the formation of the active metabolite, the follow-up may need to be prolonged, if the total dose of parent drug is substantial.

Applications of this drug in fields such as cardiac and non-cardiac surgery, cardiogenic- and septic-shock, and others have been proposed.

The effects of levosimendan in these settings have been described in many independent studies, and there is a strong rationale for suitably powered studies to corroborate those reports. Positive experience in a range of niche applications has also been documented.
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